alexa Patient Derived Xenograft Models Of Melanoma As Pre-clinical Models For Personalized Medicine
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd World Congress on Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Clemens Krepler
ScientificTracks: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.028
The approval of three drugs targeting the MAPK pathway has led to new standard therapies for melanoma with BRAFV600E mutations. The excitement about these therapeutic successes is somewhat dampened by the relapse of most if not all treated patients due to the development of acquired (secondary) resistance. Currently, there is a lack of good translational models to study resistance pathways found in patients and test novel therapies capable of achieving durable responses in patients. We have developed a patient-derived xenograft (PDX) bank for assessing patients' responses to therapies. These PDX models are established by collecting and implanting fresh biopsy tissue or fine needle aspirate (FNA) samples in NSG mice. More than 120 samples have been established in a live tumor bank characterized for mutation status and linked to clinical data including patients relapsed on BRAF inhibitors. We were able to establish PDX models from either BRAFi or BRAF/MEKi combination therapy post-relapse biopsies (RPDX). To maintain drug pressure, animals were subsequently kept on diets mimicking clinical treatment regimens at approximately clinical plasma levels. Tumors grown under these conditions maintained protein levels of key pathways compared with untreated tumors. Histologic comparison of patients? tumors and RPDX showed tumor architecture and specific antigen expression to be in concordance. RPDX models are clinically relevant tools to understand the mechanisms of resistance in tumors from individual relapsed patients. We expect that 2 nd line therapies to either of these treatment regimens will be (relatively) individualized based on patients' resistance mechanisms.
Clemens Krepler, M.D. is staff scientist in Meenhard Herlyn?s lab at the Wistar Institute, Philadelphia, PA. As a dermatologist specializing in oncology, he is focusing on translational melanoma research and personalized medicine. He has extensive experience in all aspects of melanoma management from primary diagnosis to surgical, adjuvant, and systemic therapy. In his present role, he is conducting preclinical research in targeted therapy of melanoma using advanced models such as 3D spheroid cultures and patient derived xenografts with an overarching goal of translating melanoma research into effective therapies for patients.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version